Skip to content
Clinical Trials – home
Therapeutic area

Gastrointestinal disorders – page 88

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Erosive oesophagitis

Not recruiting

Study on the Effects and Safety of Pantoprazole for Children and Teens with Healed Erosive Esophagitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Pantoprazole Sodium Sesquihydrate
  • Sponsor:Pfizer Inc.

Study on the Safety and Imaging of Adalimumab-680LT for Patients with Inflammatory Bowel Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Universitair Medisch Centrum Groningen

Colitis ulcerative

Not recruiting

Study on Mirikizumab for Children and Teens with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondation Franc.Cancerologie Digestive

Study on Calcium Chloride Hexahydrate, Irreversible Electroporation, and Pembrolizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Region Sjaelland

Colorectal cancer

Not recruiting

Study of Oxaliplatin and Nivolumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Akershus University Hospital

Study on the Safety and Effectiveness of Magrolimab with Bevacizumab and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gilead Sciences Inc.

Study of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Cogent Biosciences Inc.

Gastric cancer stage IV+2

Not recruiting

Study on Gallium (68Ga) Tezatabep Matraxetan PET for Evaluating HER2 Status in Patients with Gastro-Esophageal and HER2-Low Breast Cancer

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68Ga) Tezatabep Matraxetan
  • Sponsor:Karolinska University Hospital

Crohn's disease

Not recruiting

Study on the Safety and Effects of MBF-118 for Crohn's Disease Patients with Stenosis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mbf-118
  • Sponsor:Medibiofarma S.L.

Gastric cancer+1

Not recruiting

Study on Octreotide for Nutritional Recovery After Surgery in Esophageal or Gastric Cancer Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Octreotide
  • Sponsor:Karolinska University Hospital

Study of DKN-01 with Drug Combination for Patients with Advanced Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Leap Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.